Corneal Endothelial Dystrophy Global Market Report 2025

The corneal endothelial dystrophy market size has grown strongly in recent years. It will grow from $170.96 billion in 2024 to $185.38 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth during the historic period can be attributed to increasing healthcare expenditures, a rising prevalence of endothelial corneal dystrophy, a growing aging population, a higher incidence of eye diseases, and a surge in corneal disorders.

The corneal endothelial dystrophy market size is expected to see strong growth in the next few years. It will grow to $252.88 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The projected growth in the forecast period can be attributed to the increasing prevalence of corneal blindness in emerging economies, rising awareness about eye care, growing demand for corneal transplantation, improvements in healthcare infrastructure, and a higher incidence of chronic disorders. Key trends expected during this period include advancements in regenerative therapies, innovations in medical technology, improvements in diagnostic techniques, technological progress in ophthalmic lasers, and the development of advanced ophthalmic solutions.

The increasing demand for corneal transplantation is anticipated to drive the growth of the corneal endothelial dystrophy market. Corneal transplantation is a surgical procedure that replaces a damaged or diseased cornea with a healthy donor cornea to restore vision and enhance eye health. This rising demand is attributed to the growing prevalence of corneal diseases, advancements in surgical techniques, and improved organ donation rates. Corneal endothelial dystrophy is treated through corneal transplantation, which replaces the damaged endothelium with healthy donor tissue, restoring corneal clarity, reducing edema, and improving vision. For example, in 2023, the Eye Bank Association of America, a US-based transplant association, reported a 2.7% increase in domestic keratoplasty procedures, rising from 49,597 in 2022 to 50,925 in 2023. As a result, the increasing demand for corneal transplantation is propelling the growth of the corneal endothelial dystrophy market.

Leading companies in the corneal endothelial dystrophy market are focusing on the development of innovative treatments, such as allogeneic cell therapy, to address unmet medical needs. These innovative, minimally invasive treatment options aim to improve patient outcomes. Allogeneic cell therapy involves using cells from a genetically distinct donor of the same species to treat a recipient. For instance, in September 2024, Aurion Biotech Inc., a US-based clinical-stage biotech company, introduced Vyznova (neltependocel) in Japan for the treatment of bullous keratopathy, a corneal endothelial disease. Vyznova is a cell therapy designed to treat bullous keratopathy, which damages corneal endothelial cells and causes vision impairment. It is the first approved cell therapy for corneal endothelial disease and has received approval in Japan. Vyznova utilizes corneal endothelial cells cultured in a lab, enabling the production of up to 1,000 doses from a single donor. This innovative therapy provides a less invasive alternative to corneal transplants, helping to address the shortage of donor corneas and offering a new solution for restoring vision in patients with corneal diseases.

In February 2024, Eversight, a US-based nonprofit eye bank, collaborated with Emmecell to advance minimally invasive cell therapies for corneal endothelial diseases. This partnership aims to develop treatments for conditions such as corneal edema caused by endothelial cell dysfunction and expand access to innovative therapies worldwide. Emmecell, a US-based biotechnology company, is working on a non-surgical cell therapy to address corneal edema, a condition frequently resulting from corneal endothelial dysfunction.

Major players in the corneal endothelial dystrophy market are F. Hoffmann-La Roche AG, Abbvie (Allergan plc), Teva Pharmaceutical Industries Ltd, Fujifilm Holdings Corporation, Alcon Inc., Bausch Health+Lomb, Santen Pharmaceutical Co., Ltd., AGC Biologics Inc, Lumenis Ltd, Aurion Biotech Inc, Carl Zeiss Meditec AG, Keeler Limited, Kowa Company Ltd., ProQR Therapeutics N.V., Cellusion Inc., OptoTech GmbH, ActualEyes Inc., Arctic Vision Inc., Aurion Biotech LLC, Emmecell S.R.L.

North America was the largest region in the corneal endothelial dystrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in corneal endothelial dystrophy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the corneal endothelial dystrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Corneal endothelial dystrophy is a genetic eye disorder affecting the cornea's endothelium (inner cell layer), resulting in a gradual loss of corneal clarity. This condition is marked by the degeneration of endothelial cells, which are essential for maintaining the cornea's fluid balance.

The primary treatment options for corneal endothelial dystrophy include phototherapeutic keratectomy (PTK), amniotic membrane transplants, anterior stromal puncture, and conjunctival flaps. PTK is a laser procedure used to remove superficial corneal layers, addressing surface irregularities and scarring. These treatments are applied to various disease types, such as congenital hereditary endothelial dystrophy 1 and 2, posterior polymorphous corneal dystrophy, and Fuchs' endothelial corneal dystrophy. Diagnosis methods include corneal examination and grading, corneal tomography, corneal pachymetry, and corneal cell count. These treatments are utilized by different end-users, including hospitals, clinics, and other healthcare facilities.

The corneal endothelial dystrophy market research report is one of a series of new reports that provides corneal endothelial dystrophy market statistics, including the corneal endothelial dystrophy industry global market size, regional shares, competitors with the corneal endothelial dystrophy market share, detailed corneal endothelial dystrophy market segments, market trends, and opportunities, and any further data you may need to thrive in the corneal endothelial dystrophy industry. This corneal endothelial dystrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The corneal endothelial dystrophy market consists of revenues earned by entities by providing services such as endothelial keratoplasty, specialized contact lenses, and penetrating keratoplasty. The market value includes the value of related goods sold by the service provider or included within the service offering. The corneal endothelial dystrophy market also includes sales of medications, corneal implants, surgical instruments, diagnostic devices, cell therapy products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.